Latest News and Press Releases

On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023 Signed first global...

Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...

Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...

Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise Agreement includes upfront payment, royalties...

LOS ALTOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...

LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today...

On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in second quarter 2022 Plans to initiate Phase 1 study for UNI-494 in second half of...

LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...

On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in second half of...

LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...